Immunohistochemical Study of Neurodegenerative Diseases

• Status: Active, not recruiting
• Trial end date: 2023-04-30
• Target enrollment: 0
• Participant gender: All

Summary

The subject uses cytof to analyze PBMC of sporadic AD and DLB, which is used to reveal the differences in immune characteristics of the two diseases at the single-cell level, build immune models for specific diseases, and define these two neurodegenerative diseases with high precision from the level of molecular immunity. To provide basis for further study of the immunohistochemical differences between the two diseases, and provide objective support for clinical diagnosis and differential diagnosis.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: First Affiliated Hospital of Zhejiang University
• Treatments: Donepezil

Criteria

Inclusion Criteria:

1. AD inclusion criteria:

a.Clinical diagnosis of Alzheimer's Disease

2. DLB inclusion criteria:

1. Clinical diagnosis of Dementia with Lewy bodies

Exclusion Criteria:

1. Infectious diseases

2. autoimmune disease

3. heart failure

4. chronic obstructive pulmonary disease (COPD)

5. cancer

6. renal failure

7. recently major surgery

8. alcohol and / or drug abuse

9. disturbance of consciousness

10. clinical diagnosis of major depression disorder

11. clinical diagnosis of Anxiety disorder